-
Naunyn-Schmiedeberg's Archives of... Jun 1983
Comparative Study
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Ancitabine; Animals; Bretylium Tosylate; Cytarabine; Esterases; Histocytochemistry; Male; Mice; Mice, Inbred ICR; Norepinephrine; Renin; Submandibular Gland; Time Factors
PubMed: 6192347
DOI: 10.1007/BF00498825 -
[Hokkaido Igaku Zasshi] the Hokkaido... May 1983We analysed the effects of three different regimens for first induction therapy with 50 cases of acute nonlymphocytic leukemia in adults and reported the results of... (Comparative Study)
Comparative Study
We analysed the effects of three different regimens for first induction therapy with 50 cases of acute nonlymphocytic leukemia in adults and reported the results of combination therapy including aclacinomycin for reinduction therapy. Results obtained were as follows: The regimens of DCMP 2 step and Cc, P were superior to DCMP in remission rate (78%, 78% and 41%), median duration of CR (8.3 months, 5.0 months and 3.5 months) and survival time (6.5 months, 11.5 months and 2 months). Cc, P regimens obtained favorable CR rate in elderly patients over 50 years of age. (Cc, P: 100%, others: 40-50%) No significant difference in survival time was observed in patients who attained CR by three different regimens. In patients treated with combination therapy including aclacinomycin, the CR rate was 89% in the 9 previously treated patients (5 relapse cases and 4 refractory leukemias): All of these patients had previously been treated with DCMP 2 step or BHAC-DMP. Daunomycin (D), Cytosine Arabinoside (C), 6-Mercaptopurine (M) and Prednisolone (P) (DCMP), DCMP 2 step and Cyclocytidine (Cc) P.
Topics: Aclarubicin; Acute Disease; Adult; Age Factors; Ancitabine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone
PubMed: 6194091
DOI: No ID Found -
Cancer Treatment Reports May 1983
Topics: Adolescent; Aminoacridines; Amsacrine; Ancitabine; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Retrospective Studies
PubMed: 6189604
DOI: No ID Found -
Journal of Pharmaceutical Sciences Dec 1982First-order rate constants (kL) for hydrolysis of p-nitrophenyl acetate, cationic cyclocytidine, and anionic indomethacin in the presence of buffered liposomal...
First-order rate constants (kL) for hydrolysis of p-nitrophenyl acetate, cationic cyclocytidine, and anionic indomethacin in the presence of buffered liposomal suspensions of positive, negative, and neutral charge were compared to those determined in the corresponding buffers (kB) using the ratio, Rk = kL/kB. Association between the reactants and the liposomes was evaluated by comparing assays for concentration in the filtrates (CF) with the total concentration in the liposomal suspension (CT) using RC = CF/CT. Liposomes did not influence cyclocytidine hydrolysis rates and no association was observed (Rk congruent to RC congruent to 1). In contrast, indomethacin showed approximately 80% reduction in hydrolysis rate and approximately 80% liposome association value (Rk congruent to 0.2 congruent to RC). In neutral and negatively charged liposomal suspensions, p-nitrophenyl acetate displayed approximately 30% decrease in kB (Rk congruent to 0.7) together with approximately 90% liposomal association (RC congruent to 0.1). However, hydrolysis was greatly accelerated in positively charged liposomal suspensions. Loss was described by a biexponential equation where alpha is the fast and beta is the slow pre-exponential coefficient and alpha/beta/kB = 39:6:1. The observed relationships between hydrolysis rates and reactant-liposome associations are reconciled in terms of the hydrophilicity of the reactants and the potential influence of the liposomes on the expected transition states for the hydrolysis reactions.
Topics: Ancitabine; Buffers; Cytarabine; Drug Stability; Hydrolysis; Indomethacin; Kinetics; Liposomes; Models, Chemical; Nitrophenols; Suspensions
PubMed: 6185667
DOI: 10.1002/jps.2600711221 -
The Japanese Journal of Antibiotics Sep 1982Cyclocytidine (Cyclo-C) was evaluated as an antiviral chemotherapeutic agent in 10 children with herpes-group virus infections. The diagnoses of the patients were severe...
Cyclocytidine (Cyclo-C) was evaluated as an antiviral chemotherapeutic agent in 10 children with herpes-group virus infections. The diagnoses of the patients were severe cytomegalovirus (CMV) syndrome with pneumonitis in acute leukemia (2), congenital or infantile CMV infections (3), herpes zoster encephalitis in acute leukemia (1), severe nosocomial varicella in compromised patients (2), varicella pneumonia (1) and acute encephalitis due to herpes simplex type-1 (1). Cyclo-C was effective in all the cases with acute infections, although it had no benefit on the course of chronic CMV infection with irreversible damages. However, complete or transient ceasing of viral shedding was obtained in all the 5 cases with CMV infections. From the present small open study, further evaluation of Cyclo-C as an antiviral agent especially in acute CMV infections is warranted.
Topics: Ancitabine; Child; Cytarabine; Cytomegalovirus Infections; Female; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Infant; Male
PubMed: 6183467
DOI: No ID Found -
Gan To Kagaku Ryoho. Cancer &... Aug 1982Ara-C should be converted to ara-CTP to inhibit DNA polymerase in the malignant cells but is rapidly inactivated to uracil arabinoside (ara-U) by cytidine deaminase in... (Review)
Review
Ara-C should be converted to ara-CTP to inhibit DNA polymerase in the malignant cells but is rapidly inactivated to uracil arabinoside (ara-U) by cytidine deaminase in human tissue. Therefore, production as well as maintenance of ara-CTP in the cells is a function of both phosphorylation and deamination of ara-C, but is more dependent on the latter, because the deamination is several times superior to the former in terms of enzymatic activities. In chemotherapy with ara-C, the rate of the inactivation should be estimated for evaluating antitumor effect of the agent. Determination of serum or plasma deaminase activity can be a useful parameter of the inactivation. Attempts have been made to enhance the antitumor activity of ara-C by preventing deamination and a number of ara-C derivatives resistant to the deamination such as cyclocytidine, ara-C-5'-ester and acyl ara-C have been introduced. Cyclo-C gradually receives non-enzymatic hydrolysis to produce ara-C in neutral medium, which is useful for maintaining plasma ara-C level. Acyl ara-C such as behenoyl-ara-C (BHAC) is well incorporated into the cells and is highly distributed to lipophilic components such as membrane, microsome and mitochondria in the cells. The extremely gradual conversion of BHAC to ara-C in the cells is considered to be useful for maintaining effective intracellular concentration. A part of BHAC could be phosphorylated before deacylation. After intravenous administration of BHAC, the plasma drug concentrations are maintained significantly longer than those after the administration of the equivalent dose of ara-C. Therefore, BHAC is more resistant to the deamination than cyclo-C and the antitumor effect of the former is suspected to be milder but prolonged than that of ara-C or cyclo-C.
Topics: Ancitabine; Cytarabine; Humans; Kinetics; Leukemia
PubMed: 6191711
DOI: No ID Found -
Problemy Gematologii I Perelivaniia... Jul 1982
Clinical Trial
Topics: Ancitabine; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Humans; Leukemia
PubMed: 6181500
DOI: No ID Found -
[Rinsho Ketsueki] the Japanese Journal... Feb 1982
Topics: Ancitabine; Bone Marrow; Cytarabine; Drug Therapy, Combination; Female; Humans; Infusions, Parenteral; Leukemia; Middle Aged; Prednisolone
PubMed: 6178859
DOI: No ID Found -
Cancer Nov 1981Fifty-one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L-12 protocol. The L-12 differed from the... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Fifty-one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L-12 protocol. The L-12 differed from the preceding L-6 in that 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine (AAFC), replaced arabinosylcytosine (ara-C) together with 6-thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14-week multi-drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L-6 regimen. Four year disease-free survival was 22% on the L-12 compared with 16% on the L-6 protocol. No relationship between prognosis and FAB classification was found on either the L-6 or the L-12 protocol.
Topics: Adolescent; Adult; Aged; Ancitabine; Antineoplastic Agents; Bacterial Vaccines; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Pseudomonas aeruginosa; Random Allocation; Thioguanine
PubMed: 6170414
DOI: 10.1002/1097-0142(19811115)48:10<2136::aid-cncr2820481003>3.0.co;2-1 -
[Zhonghua Yan Ke Za Zhi] Chinese... Sep 1981
Topics: Adolescent; Adult; Ancitabine; Cytarabine; Female; Humans; Keratitis, Dendritic; Male; Middle Aged
PubMed: 6174279
DOI: No ID Found